Complete responses were seen in 14% of patients with head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC); 65% ...
Conditioned media from liver cells treated with the phosphoeleganin-derived compound PE/2 improved cytokine balance, lipid ...
A meta-analysis of six randomized trials found that adding PD-1/PD-L1 inhibitors to chemotherapy was associated with longer ...
Responses were deep and durable, with 65% ongoing at clinical cutoff; Results support continued evaluation of the ...
Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both ...
Results of New York Times/Philadelphia Inquirer/Siena polls conducted among 1,607 voters from Oct. 16 to 22, 2026.
BioNTech and Bristol Myers report 36.7% confirmed response with pumitamig plus docetaxel in 30 evaluable patients, without a ...
Lilly reports a 62% response rate with an olomorasib lung-cancer combination. Randomized SUNRAY-01 results are expected in ...
Positive results from the SAFFRON Phase III trial showed Tagrisso (osimertinib) plus Orpathys (savolitinib) demonstrated a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results